Clinical cancer research : an official journal of the American Association for Cancer Research · 2005
Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Schaijk Frank G, Oosterwijk Egbert, Soede Annemieke C, Broekema Matthias, Frielink Cathelijne, McBride William J, Goldenberg David M, Corstens Frans H M, Boerman Otto C
Аннотация
PURPOSE: The aim of these studies was to develop a pretargeting strategy for CEA-expressing cancers using biologically produced bispecific monoclonal antibodies (bsMAb). The bsMAbs used in this system have affinity for the carcinoembryonic antigen on the one hand, and for indium-labeled diethylenetriaminepentaacetic acid (DTPA), on the other.
EXPERIMENTAL DESIGN: Stable quadroma clones producing bsMAb MN-14xDTIn-1 were isolated. LS174T tumor-bearing mice were injected with 1 to 100 microg of bsMAb followed by 1 to 60 ng of an (111)In-labeled bivalent peptide [Ac-Phe-Lys(DTPA)-Tyr-Lys(DTPA)-NH2]. Mice were killed at 24 hours postinjection and the biodistribution of the radiolabel was determined. The biodistribution of diDTPA labeled with four different radionuclides ((111)In, 99mTc, nonresidualizing 125I, and residualizing 125I) was determined at various time points postinjection following pretargeting of LS174T tumors with bsMAb MN-14xDTIn-1.
RESULTS: Optimal tumor targeting was observed when tumors were pretargeted with 10 microg of bsMAb MN-14xDTIn-1 and when 6 ng of a radiolabeled peptide was given 72 hours later. The uptake of the four radiolabels in LS174T tumors at 4 hours postinjection was similar. However, at later time points, the (111)In-label and residualizing 125I-label were better retained in the tumor than the nonresidualizing 125I label. Although the absolute uptake in the tumor (in terms of percentage of injected dose per gram of tissue) was 5-fold lower than the uptake obtained with directly labeled MN-14, the pretargeting strategy revealed much higher tumor-to-blood ratios due to the rapid clearance of the radiolabel from the circulation as compared with (111)In-MN-14 (445 +/- 90 and 5.3 +/- 1.1, respectively, at 72 hours postinjection).
CONCLUSIONS: Effective targeting of carcinoembryonic antigen-expressing tumors was achieved with a newly produced bispecific antibody. The (111)In-labeled L-amino acid peptide and 125I-D-amino acid peptide were better retained in the tumor than the 99mTc- and 125I-L-amino acid peptide. Very high tumor-to-blood ratios were obtained due to rapid background clearance.
EXPERIMENTAL DESIGN: Stable quadroma clones producing bsMAb MN-14xDTIn-1 were isolated. LS174T tumor-bearing mice were injected with 1 to 100 microg of bsMAb followed by 1 to 60 ng of an (111)In-labeled bivalent peptide [Ac-Phe-Lys(DTPA)-Tyr-Lys(DTPA)-NH2]. Mice were killed at 24 hours postinjection and the biodistribution of the radiolabel was determined. The biodistribution of diDTPA labeled with four different radionuclides ((111)In, 99mTc, nonresidualizing 125I, and residualizing 125I) was determined at various time points postinjection following pretargeting of LS174T tumors with bsMAb MN-14xDTIn-1.
RESULTS: Optimal tumor targeting was observed when tumors were pretargeted with 10 microg of bsMAb MN-14xDTIn-1 and when 6 ng of a radiolabeled peptide was given 72 hours later. The uptake of the four radiolabels in LS174T tumors at 4 hours postinjection was similar. However, at later time points, the (111)In-label and residualizing 125I-label were better retained in the tumor than the nonresidualizing 125I label. Although the absolute uptake in the tumor (in terms of percentage of injected dose per gram of tissue) was 5-fold lower than the uptake obtained with directly labeled MN-14, the pretargeting strategy revealed much higher tumor-to-blood ratios due to the rapid clearance of the radiolabel from the circulation as compared with (111)In-MN-14 (445 +/- 90 and 5.3 +/- 1.1, respectively, at 72 hours postinjection).
CONCLUSIONS: Effective targeting of carcinoembryonic antigen-expressing tumors was achieved with a newly produced bispecific antibody. The (111)In-labeled L-amino acid peptide and 125I-D-amino acid peptide were better retained in the tumor than the 99mTc- and 125I-L-amino acid peptide. Very high tumor-to-blood ratios were obtained due to rapid background clearance.
Предметные рубрики MeSH
AnimalsAntibodies, BispecificAntibodies, MonoclonalCarcinoembryonic AntigenCationsCell Line, TumorChromatography, Ion ExchangeDose-Response Relationship, DrugFemaleHumansHybridomasIndium RadioisotopesIodine RadioisotopesMiceMice, Inbred BALB CModels, StatisticalNecrosisPentetic AcidPeptidesRadioimmunotherapyRadionuclide ImagingTechnetiumTime FactorsTissue Distribution